Rallybio (RLYB) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 268.7% versus a loss of 30.3%. Rallybio is the larger company by market cap ($90.3 million vs $83.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RLYB | TELO |
|---|---|---|
| Share price | $16.99 | $1.14 |
| Market cap | $90.26M | $83.92M |
| 1-day change | 0.00% | -0.87% |
| YTD return | +209.58% | -13.53% |
| 1-year return | +268.71% | -30.30% |
| 5-year return | -86.32% | — |
| P/E ratio (TTM) | 2.12 | — |
| EPS (TTM) | $8.01 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.57 | $1.82 |
| 52-week low | $3.67 | $0.888 |
| Distance from 52-week high | -3.32% | -37.26% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +250.88% |
| Average volume | 21.33K | 97.98K |
| Shares outstanding | 5.31M | 73.62M |
| Employees | 7 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed TELO by 299.0 percentage points over the past year.
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
RLYB vs TELO FAQ
Which is bigger, Rallybio or Telomir Pharmaceuticals?
Rallybio (RLYB) is larger, with a market capitalization of $90.26M compared with $83.92M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, RLYB or TELO?
RLYB returned +268.71% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Rallybio and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.